
        <!DOCTYPE html>
        <html>
        <head>
            <title>Biogen Inc. (BIIB) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Biogen Inc. (BIIB)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">‚Üê Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">42</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">17</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">11</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.10</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e9479e4add711224ea8bea7f18235d31ab0d90d0cfbd714f3fa974dbf498ffcb" target="_blank" rel="noopener noreferrer">Biogen starts dosing in Phase III trial of Friedreich ataxia therapy</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f390a8c5e439f2b9784a6dd23eed484e40011aa2b11d99e329f717a4a50a3b80" target="_blank" rel="noopener noreferrer">Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-18</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.30
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich.....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a9180bd7d02f1c9c1fe8855714656f55e8a8d290868a380c3c9dc77b1745b62f" target="_blank" rel="noopener noreferrer">Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the p...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7181103317f95e019e4fb5b35d7040ff84952b6684810f7dccc685786f680136" target="_blank" rel="noopener noreferrer">H.C. Wainwright sees potential competition for Sage from Biogen</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and ‚Äúleaves open the door for additiona...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0ad2e92c40632fbf0a4d0550ea11ff0cc4ddb1c12d7fa2e21b1aebc634b6789e" target="_blank" rel="noopener noreferrer">21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.80
                                </span>
                            </div>
                            <div class="article-summary">CANNES, France & NEW YORK, June 18, 2025--21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival of Creativity...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3226d261de07a5bc2f138fb81f7b88ae6a65968b8080612979fc6ef6cb7de477" target="_blank" rel="noopener noreferrer">Maxion Therapeutics Appoints Dr. Stefan H√§rtle as Chief Development Officer</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-17</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Cambridge, UK, 17 June 2025 ‚Äì Maxion Therapeutics (‚ÄúMaxion‚Äù), a biotechnology company developing antibody-based KnotBody¬Æ drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, t...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=dd08a992e71b0b2b7d198729e9d5b314c14b5a8324e30ffd37ff51cf60a0252a" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Tuesday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-17</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Tuesday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3f8dac17c4a9a3d7a6768d96791db41f86a97b685610ce68665ca1d6bf746979" target="_blank" rel="noopener noreferrer">SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-17</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.52
                                </span>
                            </div>
                            <div class="article-summary">SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=60767a67e291a846633e1d00db4e64ce83a2af5a20489afa45309ea47496aac5" target="_blank" rel="noopener noreferrer">Supernus enters depression drug market with up to $795 million Sage deal</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-16</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.51
                                </span>
                            </div>
                            <div class="article-summary">Supernus Pharmaceuticalswill acquire Sage Therapeutics in a deal worth up to$795 million, gaining access to the only postpartum depressionpill approved in the United States, the companies said......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e8308bd99ce787593d343064c0bfc939cfe451b4b0532e0ebc07d8b5c14933cf" target="_blank" rel="noopener noreferrer">Sage, following Setbacks, to sell to Supernus for $561M</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-16</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.53
                                </span>
                            </div>
                            <div class="article-summary">In what one analyst described as an ‚Äúunremarkable‚Äù outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6b1eedda9c38b5d71db8b5755b69a9897e880afb66630dd315494a7d449fff24" target="_blank" rel="noopener noreferrer">Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-16</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.64
                                </span>
                            </div>
                            <div class="article-summary">Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal worth up to $561 million....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=91f85fdcb8c190e075ef3f8f99231b7897062bb487712d81d2115f61d739b2e0" target="_blank" rel="noopener noreferrer">Supernus makes depression drug play with $795m Sage buyout</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-16</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a3d07d5487e406a6b43a526c930a8600e63bba45102f381261c9dd01edbb44e4" target="_blank" rel="noopener noreferrer">Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-16</span>
                                <span>DowJones</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=14ec0f8cb2231444090d6225bcbf24a2096e414cc6707a93cb31e81e5924baef" target="_blank" rel="noopener noreferrer">Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-15</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dap...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=adc97fbc49d122525659392302cc20f65243377a928325db6f7f7bd6d0393742" target="_blank" rel="noopener noreferrer">1 Profitable Stock with Exciting Potential and 2 to Avoid</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.57
                                </span>
                            </div>
                            <div class="article-summary">A company with profits isn‚Äôt always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4a2a84381dfb375c254c97093cac789fb62e60e82023fc9f3f25e22b8b2b8289" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Friday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-13</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Friday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9369c1f4fb2438e1d3737be6c3b1285a7933c98b4105b7f7e79d39c7d1c7d489" target="_blank" rel="noopener noreferrer">Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-12</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.80
                                </span>
                            </div>
                            <div class="article-summary">Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=25c6750499650517d00436206548002809363ab890d43691826e63252333bacd" target="_blank" rel="noopener noreferrer">Biogen: positive Phase 3 data in lupus</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-12</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">Biogen and UCB have announced additional detailed results from the Phase 3 PHOENYCS GO study evaluating their investigational drug dapirolizumab pegol at the annual meeting of the European League......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9bd46aa422c7c828c4d302b074c969b75a1737fa5db68a84075402511b587eae" target="_blank" rel="noopener noreferrer">Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases including Three Phase 3 Programs in Rare KidneyDiseases</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-12</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.75
                                </span>
                            </div>
                            <div class="article-summary">Cambridge - Biogen Inc. will host a virtual investor seminar today at 10:00 a.m. ET focused on the potential of the investigational drug felzartamab in rare kidney diseases and the potential to......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fc851852e3846c7b0b330c94b4f52f103eaeafbad94cdd7413f68f425bcc0bc2" target="_blank" rel="noopener noreferrer">Worldwide Healthcare Trust trails benchmark in "challenging" year</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.23
                                </span>
                            </div>
                            <div class="article-summary">Worldwide Healthcare Trust PLC on Wednesday reported that its total return for 2025 was below its benchmark, amid a period of turbulence for medical sectors.The London-based investor in global......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=da2a913bbbfe7acb1d054fc8a0da9164ba9ed1331319c2d4f4feba27f5238dd2" target="_blank" rel="noopener noreferrer">Biogen : Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.81
                                </span>
                            </div>
                            <div class="article-summary">Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases ......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0e51aa293b7a77d68e5cc74ed7ee3b4724117d3bdad203e2194eba216cbf6986" target="_blank" rel="noopener noreferrer">Biogen Thematic Pipeline Seminar: Rare Kidney Disease</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">June 11, 2025 BIOGEN THEMATIC PIPELINE SEMINAR RARE KIDNEY DISEASE ......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=592dac0181aec5c50ac27508fa2c6132ec1dbc930a203760a9cacfcdf1c45c41" target="_blank" rel="noopener noreferrer">Transcript : Biogen Inc. - Special Call</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Presentation Operator MessageOperator Good morning. My name is Shelly, and I will be your conference operator today. Biogen Thematic Pipeline Seminar, Rare Kidney Disease. [Operator Instructions]......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9219f5509081227cc65d5eccad36dedbf1fe5a4230e3e9cbdb7150bab4d7191b" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Wednesday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-11</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.91
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Wednesday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=df1c4f8a8a04340aca0b4d52717a3548ae2a56c923a984ad7f1a77f3b0977d84" target="_blank" rel="noopener noreferrer">Transcript : Biogen Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-10</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Presenter SpeechSalveen Richter Great. Good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs and really pleased to have with us Robin......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d2f62563557ba3056a4ee47606b2537584cb1fe190d84a98701d62e7348df573" target="_blank" rel="noopener noreferrer">Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-10</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ETCompany ParticipantsRobin C....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9f44526e9dc0c3ba2c7e7c2d14ca08ae9c92b6ace1a1888bdd61cc6d8e9b694c" target="_blank" rel="noopener noreferrer">Biogen Inc. stock outperforms competitors on strong trading day</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-06</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock outperforms competitors on strong trading day...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=27c25d966e811b2ffc37491bf3e1b81d584ef4da3f56dbf2b62bc8de1c94d7f1" target="_blank" rel="noopener noreferrer">Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-05</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.39
                                </span>
                            </div>
                            <div class="article-summary">Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0f37203c785ec6e1cccb618e1a08abff500501d39b425a8bba3ca62b928dd14b" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Thursday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-05</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Thursday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=38a3fa6a8cead9c9e75f77bfc020116de74993e8dc05a0e0b75137cad50c9df0" target="_blank" rel="noopener noreferrer">abrdn World Healthcare Fund Q1 2025 Commentary</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-03</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.56
                                </span>
                            </div>
                            <div class="article-summary">The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ffbbd1d9d0ee42f7282b6240d93b09824516bf8fc1547da4f1cdfa8aeebce746" target="_blank" rel="noopener noreferrer">Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Bo...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8f277ff4a23eb1a9d0a073121fe3f8808f7909282b7e596f16af16b15f12e51c" target="_blank" rel="noopener noreferrer">Biogen : to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-03</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Cambridge, MA, - - Biogen Inc. announced today that Robin Kramer, Chief Financial Officer, will participate in a fireside chat during the Goldman Sachs 46th Annual Global Healthcare Conference. The......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e17dcc444ba7286ea5d30c896b29e0cf8eb2249f5a104b4b378012088b5ef637" target="_blank" rel="noopener noreferrer">Biogen Files Suit Against Neurimmune Over Rights To Bispecific Antibody</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-02</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.68
                                </span>
                            </div>
                            <div class="article-summary">On May 13, 2025, Biogen Inc. and Biogen MA Inc. filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief against Neurimmune Holding AG and Neurimmune SubOne AG in the U.S. District.....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6a43801cb46ae43d45b78fba22426c61b25efdf36ba75aa6357f4220e9041fb1" target="_blank" rel="noopener noreferrer">abrdn Life Sciences Investors Q1 2025 Commentary</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-31</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5e602a9d616ac83a6a50a36419ece3ad23b7b2a464982b92055c69e8d8bb99b2" target="_blank" rel="noopener noreferrer">Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-30</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.38
                                </span>
                            </div>
                            <div class="article-summary">The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let‚Äôs take a look at how therapeutics stocks fared in Q1, starting with Biogen (NASDA...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1e7d92db3a9a6deb916832c5a4b060682f0d92a3ed0504842b833e4bd3cc2df2" target="_blank" rel="noopener noreferrer">Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-28</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB)‚Äôs recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases has fueled a 6% rise in its share price over the past month, r...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6c68e5c45080a99900b4d143e8b1dda69a1509d110140e403aa928ad9e819def" target="_blank" rel="noopener noreferrer">Biogen and City Therapeutics to develop RNAi therapy</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-28</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=04774730757f1fa40e6bfb98d905333f1c463c975d55eb867abca3d03244ac7e" target="_blank" rel="noopener noreferrer">Biogen to Pay $46M in RNAi-Development Collaboration</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-27</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen to Pay $46M in RNAi-Development Collaboration...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f07b8686f8311dee720d196e8677ec9f7315db42f5258960e4751dbdcc79e679" target="_blank" rel="noopener noreferrer">Biogen Inc. and City Therapeutics, Inc. Announce Strategic Research Collaboration to Develop Select Novel Rnai-Based Therapies</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-27</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop select novel RNAi therapies. Through the collaboration, City Therapeutics will leverage its next-generation RNAi....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=03dca823c5463f9f58641193c57453a1944a42631a20b86d87eb10705cd334d5" target="_blank" rel="noopener noreferrer">Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.81
                                </span>
                            </div>
                            <div class="article-summary">Collaboration leverages City Therapeutics‚Äô next-generation RNAi engineering technologies and Biogen‚Äôs extensive drug development expertiseCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=cd21c55484ebafe468cda9858349ebebfc8492481f352b5cad67683d3ec7b474" target="_blank" rel="noopener noreferrer">Biogen strikes RNAi deal with City; Aurion withdraws IPO</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.37
                                </span>
                            </div>
                            <div class="article-summary">City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3a516df6f6a2f4bdd4b6a35401ade22a30a38181e992382a0234a75784023aab" target="_blank" rel="noopener noreferrer">Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Biogen (NasdaqGS:BIIB) recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        